Bolt Biotherapeutics (BOLT) Competitors $5.91 -0.09 (-1.50%) Closing price 07/2/2025 03:56 PM EasternExtended Trading$6.06 +0.15 (+2.45%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock BOLT vs. CRIS, SABS, CBIO, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIBShould you be buying Bolt Biotherapeutics stock or one of its competitors? The main competitors of Bolt Biotherapeutics include Curis (CRIS), SAB Biotherapeutics (SABS), GlycoMimetics (CBIO), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. Bolt Biotherapeutics vs. Its Competitors Curis SAB Biotherapeutics GlycoMimetics Molecular Templates Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Is BOLT or CRIS more profitable? Bolt Biotherapeutics has a net margin of 0.00% compared to Curis' net margin of -376.08%. Curis' return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bolt BiotherapeuticsN/A -94.51% -59.07% Curis -376.08%N/A -97.14% Which has more volatility and risk, BOLT or CRIS? Bolt Biotherapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.6, indicating that its stock price is 260% more volatile than the S&P 500. Do analysts rate BOLT or CRIS? Bolt Biotherapeutics presently has a consensus price target of $50.00, indicating a potential upside of 746.02%. Curis has a consensus price target of $17.00, indicating a potential upside of 871.43%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bolt Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Curis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in BOLT or CRIS? 86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 6.1% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 5.5% of Curis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, BOLT or CRIS? Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBolt Biotherapeutics$7.69M1.48-$63.12M-$33.40-0.18Curis$10.91M1.68-$43.39M-$6.23-0.28 Does the media prefer BOLT or CRIS? In the previous week, Curis had 1 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 1 mentions for Curis and 0 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 1.89 beat Curis' score of 0.94 indicating that Bolt Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Bolt Biotherapeutics Very Positive Curis Positive SummaryCuris beats Bolt Biotherapeutics on 9 of the 15 factors compared between the two stocks. Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BOLT vs. The Competition Export to ExcelMetricBolt BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.50M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.1821.3126.2319.90Price / Sales1.48278.47413.23113.66Price / CashN/A41.4736.1356.90Price / Book0.207.518.045.38Net Income-$63.12M-$55.05M$3.15B$248.50M7 Day Performance2.78%2.07%1.44%2.04%1 Month Performance-2.64%4.84%3.62%4.84%1 Year Performance-59.80%5.37%34.68%20.23% Bolt Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BOLTBolt Biotherapeutics2.9386 of 5 stars$5.91-1.5%$50.00+746.0%-59.8%$11.50M$7.69M-0.1890Positive NewsCRISCuris2.8104 of 5 stars$2.15-0.5%$17.00+690.7%-72.0%$22.60M$10.91M-0.3560News CoverageGap DownSABSSAB Biotherapeutics3.6973 of 5 stars$1.76-1.7%$13.25+652.8%-38.8%$16.63M$1.32M-0.48140Positive NewsGap UpCBIOGlycoMimetics3.2961 of 5 stars$15.30+2.0%$22.00+43.8%N/A$9.68M$10K0.0026News CoverageMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260AMGNAmgen4.2689 of 5 stars$272.44-5.8%$309.22+13.5%-4.5%$155.57B$33.42B24.8628,000Positive NewsHigh Trading VolumeGILDGilead Sciences4.8426 of 5 stars$106.19-2.1%$110.55+4.1%+63.0%$134.97B$28.75B22.3617,600Positive NewsInsider TradeVRTXVertex Pharmaceuticals4.6674 of 5 stars$443.54+0.6%$513.14+15.7%-3.5%$113.21B$11.02B-113.156,100Positive NewsREGNRegeneron Pharmaceuticals4.9397 of 5 stars$511.92+0.4%$836.48+63.4%-47.6%$55.03B$14.20B13.0315,106Trending NewsAnalyst DowngradeALNYAlnylam Pharmaceuticals4.2986 of 5 stars$313.13+1.1%$319.58+2.1%+33.2%$40.38B$2.25B-149.822,230Positive NewsAnalyst ForecastBIIBBiogen4.9573 of 5 stars$124.76-1.8%$188.19+50.8%-41.8%$18.61B$9.68B12.327,605 Related Companies and Tools Related Companies Curis Alternatives SAB Biotherapeutics Alternatives GlycoMimetics Alternatives Molecular Templates Alternatives Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Alnylam Pharmaceuticals Alternatives Biogen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BOLT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
